Key result
Downregulated serum GAS6-AS1 accurately identifies CHF with an AUC of ~0.89 vs healthy controls.
Why the study?
The diagnostic significance of LncRNA GAS6-AS1 in chronic heart failure and its molecular mechanism of influencing cardiomyocyte function through miR-152-3p regulation remained to be explored.
Does serum LncRNA GAS6-AS1 accurately diagnose chronic heart failure, and does it regulate cardiomyocyte injury in vitro?
Case-Control (n=250)
No
Does serum LncRNA GAS6-AS1 accurately diagnose chronic heart failure, and does it regulate cardiomyocyte injury in vitro?
Answers are grounded in this paper and cite their sources.
GAS6-AS1 is a potential non-invasive diagnostic biomarker for chronic heart failure and exerts a protective role against doxorubicin-induced cardiomyocyte injury by targeting miR-152-3p.
OBJECTIVE: To explore the diagnostic significance of LncRNA GAS6-AS1 in chronic heart failure (CHF) and its molecular mechanism of influencing cardiomyocyte function through the regulation of miR-152-3p. METHODS: This study incorporated 126 patients diagnosed with CHF and 124 healthy control subjects. The serum level of GAS6-AS1 was determined via RT-qPCR, and its diagnostic efficacy was assessed through ROC curve. A cell injury model was established by stimulating H9c2 cells with DOX. CCK-8, flow cytometry and RT-qPCR were used to analyze the effects of these on cell viability, apoptosis and inflammatory factors (TNF-α, IL-6, IL-1β). The targeting relationship between GAS6-AS1 and miR-152-3p was verified by DLR. RESULTS: The expression of GAS6-AS1 in the serum of CHF patients was significantly downregulated. ROC analysis showed that the sensitivity of GAS6-AS1 in the diagnosis of CHF was 84.90%, the specificity was 77.40%, and the AUC was 0.888 (95% CI: 0.849-0.928). Overexpression of GAS6-AS1 could mitigate the reduction in cell viability and the elevation in apoptosis induced by DOX in H9c2 cells, and inhibit the expression of pro-inflammatory factors. GAS6-AS1 could directly bind to miR-152-3p. Overexpression of miR-152-3p could reverse the inhibitory effect of GAS6-AS1 on cell apoptosis and the release of inflammatory factors. CONCLUSION: GAS6-AS1 can act as a potential diagnostic biomarker for CHF. It might accomplish this by targeting and suppressing miR-152-3p, thus decreasing cardiomyocyte apoptosis and inflammatory reactions.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a case-control in Chronic heart failure (CHF) (n=250). Serum GAS6-AS1 level vs. Healthy controls was evaluated on Diagnostic efficacy of GAS6-AS1 for CHF (AUC 0.888, 95% CI 0.849-0.928, p=<0.0001). Serum GAS6-AS1 expression was downregulated in CHF patients and demonstrated high diagnostic accuracy for differentiating CHF from healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: